PA
AEGR

Perceptive Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

Perceptive Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-100,000
Closed -$3.21M – 152
2014
Q2 		$3.21M Buy
+100,000
New +$3.72M 0.31% 54

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Perceptive Advisors's AEGR Position: Q2 2015 in Review

Perceptive Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2015, closing a stake of 381,100 shares — an estimated $9.97M sold.

Perceptive Advisors first reported a position in AEGR in Q2 2013 and held it in 5 quarters. The position peaked at $226M in Q2 2013. 97 funds tracked by Wall St. Rank hold AEGR as of Q2 2015.

  • Perceptive Advisors reported no remaining Aegerion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Perceptive Advisors sold 381,100 Aegerion Pharmaceuticals shares in Q2 2015, an estimated $9.97M.
  • Perceptive Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Perceptive Advisors's Aegerion Pharmaceuticals position peaked at $226M in Q2 2013.
  • 97 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2015.

Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.